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1004Objective: The optimal treatment of multivessel coronary artery disease is not well established. Hybrid coro-
nary revascularization by combining the left internal mammary artery–left anterior descending artery graft and
drug-eluting stents in non–left anterior descending artery territories might offer superior results compared with
sole coronary artery bypass grafting or sole percutaneous coronary intervention.
Methods: We retrospectively analyzed the 30-day outcomes of 381 consecutive patients undergoing coronary
artery bypass grafting (n ¼ 301) vs hybrid coronary revascularization (n ¼ 80). In a 2 3 2 matrix, the 2 groups
were stratified by the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery
(SYNTAX) score (32 vs33) and the European System for Cardiac Operative Risk Evaluation (euroSCORE)
(<5 vs 5). The composite endpoint (death from any cause, stroke, myocardial infarction, low cardiac output
syndrome) and secondary endpoints (worsening postprocedural renal function and bleeding) were determined.
Results: After stratification using the SYNTAX and the euroSCORE, the preoperative characteristics were sim-
ilar within the 4 groups, except for the 33 SYNTAX/>5 euroSCORE. The hybrid coronary revascularization
patients were older (77 vs 65 years, P ¼ .001). The postoperative outcomes using combined SYNTAX and the
euroSCORE stratification showed a similar rate of the composite endpoint for all groups except for patients with
33 SYNTAX/>5 euroSCORE (0% for the coronary artery bypass grafting group vs 33% for the hybrid cor-
onary revascularization group, P¼ .001). An analysis of the secondary endpoint showed similar results across all
groups, except for in the 33 SYNTAX/>5 euroSCORE group, in which bleeding (re-exploration for bleeding
and transfusion>3 packed red blood cell units per patient) was 44% in the hybrid coronary revascularization
group vs 11% in the coronary artery bypass grafting group (P ¼ .05).
Conclusions: Hybrid coronary revascularization is a safe alternative to coronary artery bypass grafting in many
patients with multivessel coronary artery disease. However, in high-risk patients with complex coronary artery
disease (33 SYNTAX/>5 euroSCORE), coronary artery bypass grafting is superior to hybrid coronary
revascularization. (J Thorac Cardiovasc Surg 2013;145:1004-12)Earn CME credits at
http://cme.ctsnetjournals.org
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The Journal of Thoracic and Cardiovascular Surpatients with diabetes and complex lesions, primarily owing
to the left internal mammary artery (LIMA) to the left
anterior descending (LAD) artery graft.1,2 The excellent
long-term patency of the LIMA-LAD graft contrasts with
the rate of early saphenous vein graft (SVG) failure
(6.2%–30% at 12 months),2-4 which might account for
the durable clinical benefit of CABG. In non-LAD coronary
arteries, the 12-month rate of drug-eluting stent (DES)
restenosis and thrombosis after percutaneous coronary in-
tervention (PCI) is lower than the rate of SVG failure.5
Therefore, PCI with DES might be a reasonable alternative
to SVG for revascularization of non-LAD coronary arteries.
Thus, hybrid coronary revascularization (HCR), com-
bining the LIMA-LAD graft and DES to non-LAD vessels,
might become a superior revascularization alternative in
multivessel CAD. Several observational studies, including
Vanderbilt’s experience,6 have demonstrated that a hybrid
strategy is safe, with short-term outcomes similar to those
of standard CABG. However, the indication for, and safety
of, HCR compared with standard CABG are not wellgery c April 2013
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BMS ¼ bare metal stent
CABG ¼ coronary artery bypass grafting
CAD ¼ coronary artery disease
DES ¼ drug-eluting stent
HCR ¼ hybrid coronary revascularization
LAD ¼ left anterior descending (artery)
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MACCE ¼ major adverse cardiovascular and
cerebral events
PCI ¼ percutaneous coronary artery
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Leacche et al Acquired Cardiovascular Disease
A
C
Destablished. In the present study, we compared the 30-day
outcomes of HCR and standard CABG in patients stratified
by the complexity of CAD (Synergy Between Percutane-
ous Coronary Intervention With Taxus and Cardiac Sur-
gery [SYNTAX] score)2,7 and surgical risk profile
(European System for Cardiac Operative Risk Evaluation
[euroSCORE]).8METHODS
After obtaining institutional review board approval, we retrospectively
collected data for 500 consecutive patients who had undergone CABGwith
or without concomitant PCI from April 2005 to March 2009. Patients with
multivessel CAD involving the LAD artery and at least 1 other major
epicardial artery or left main disease were included in the present study.
Patients with concomitant valvular surgical procedures (n ¼ 31), single-
vessel CAD (n¼ 33), previous CABGwith patent grafts (n¼ 9), PCI with-
out stenting as a ‘‘bridge’’ to CABG (n ¼ 2), or post-CABG PCI (n ¼ 27)
were excluded. Preprocedural coronary angiographic data were not avail-
able for review in 8 patients. Thus, 301 CABG and 80 HCR patients
from our group practice were analyzed in the present study. The SYNTAX
score for each patient was calculated by 2 cardiologists using the SYNTAX
score algorithm, as previously described.7 The euroSCORE for each pa-
tient was also calculated.8 Patients were stratified into 4 groups according
to the SYNTAX score (32 vs 33) and euroSCORE (5 vs>5).
A comparison between CABG and HCR within these 4 risk-stratified
groups was performed. The primary clinical endpoint was a composite ma-
jor adverse cardiovascular and cerebral events (MACCE) endpoint, includ-
ing death from any cause, stroke, myocardial infarction, and low cardiac
output syndrome during the 30 days after the procedure. The secondary
clinical endpoints wereworsening postprocedural renal function and bleed-
ing complication during the 30 days after procedure.
All patients enrolled in the study were referred for coronary artery
bypass surgery according to the clinical indications. For HCR, the cardiac
surgeon and interventional cardiologist both reviewed the coronary
angiographic data in advance. The hybrid approach was presented as an al-
ternative approach to CABG to the patient, and separate consent was ob-
tained. Patients who underwent a planned hybrid procedure received 300
mg of clopidogrel immediately before induction. A total of 20 patients
(25%) underwent an ‘‘unplanned’’ hybrid procedure that was performed
because of intraoperative findings such as graft defects on completion angi-
ography, poor conduits, or a poor target vessel. The unplanned hybrid pa-
tients received 300 mg clopidogrel by way of a nasogastric tube at PCI.The Journal of Thoracic and CarPatients who received stents to the graft conduits (SVG or LIMA, n ¼ 27)
or native LAD (because of a failed LIMA-LAD graft, n¼ 2) were excluded
from the present analysis. Patients who received stents to non-LAD native
vessel because of failed SVG grafts (n ¼ 4) were included in the analysis.
All hybrid patients received clopidogrel 75 mg/day for at least 12 months.
Unfractionated heparin was used for both PCI and CABG. Heparin was re-
versed by protamine at the end of CABG in all patients. A sheath had been
placed in the left or right femoral artery using the modified Seldinger tech-
nique before anticoagulation with heparin. At the end of surgery, the sheath
was removed after the heparin was reversed with protamine, and a Syvek
Patch (Marine Polymer Technologies, Danvers, Mass) was applied with
12 minutes of manual compression of the groin.
Statistical Analysis
The data are expressed as the mean standard deviation or percentages.
For continuous variables, aMann-WhitneyU test was used, and the data are
expressed as the median. The 2-tailed Fischer exact test was used for
categorical variables. Data analysis and statistical analysis were performed
using STATA, version 9.0 for Windows (StataCorp, College Station, Tex).RESULTS
Stratification by SYNTAX Score Only
Patients with SYNTAX score of 32 or less. A total of 293
patients (226 CABG, 67 HCR) had a SYNTAX score of 32
or less (mean, 21  8). The HCR group had more 3-vessel
CAD (82% vs 66%, P ¼ .015), and the CABG group had
more 2-vessel CAD (30% vs 15%, P ¼ .018). Compared
with the CABG group, the HCR group had shorter aortic
crossclamp ischemic times but a longer total operative
time. Other preoperative, intraoperative, and postoperative
data were similar among the groups (Table 1). In the HCR
group, of 67 patients, 62 (93%) received a DES and 7
(7%) of 69 patients received a bare metal stent (BMS).
Each patient received a mean of 2 1.3 stents. The median
number of bypass grafts per patient was 2 in each group
(HCR and CABG patients).
Patients with SYNTAX score of 33 or greater. A total of
88 patients (75 CABG, 13 HCR) had a SYNTAX score of 33
or greater (mean, 37 4). Compared with patients undergo-
ingCABG, the patients undergoingHCRwere older (median
age, 74 vs 62 years; P¼ .015) and had a greater euroSCORE
(median, 6 vs 4; P ¼ .045). The cardiopulmonary bypass
time and ischemic times were shorter in the HCR group
than in the CABG group. The composite MACCE was
greater in the HCR group than in the CABGgroup, primarily
owing to increased mortality in the HCR group (HCR, 3/13
[23%] vs CABG, 0/75 [0%]; P¼ .003; Table 2). The mean
number of stents per patient in theHCR groupwas 2.3 0.8,
with 77% (10/13) receiving DES and 23% (3/13) receiving
BMS. The median number of grafts per patient in the CABG
group was 2 (range, 1–5) and 1 (range, 1–2) in the HCR
group (P ¼ .001; Table 2).Stratification by euroSCORE Only
Patients with euroSCORE of 5 or less. A total of 239 pa-
tients (193 CABG and 46 HCR) had a euroSCORE of 5 ordiovascular Surgery c Volume 145, Number 4 1005
TABLE 1. Preoperative, intraoperative, and postoperative data for
SYNTAX 32 (n ¼ 293)
Variable
CABG
(n ¼ 226)
HCR
(n ¼ 67)
P
value
Preoperative data
Age (y) 63 (32–89) 62 (39–85) .707
Men 169 (75) 53 (79) .519
Diabetes 86 (38) 28 (42) .669
Hypertension 186 (82) 59 (88) .348
Dyslipidemia 170 (75) 49 (73) .750
Cardiogenic shock 3 (1) 1 (1) 1.000
CHF 25 (11) 5 (7) .495
COPD 48 (21) 17 (26) .502
History of stroke 18 (8) 3 (4) .427
PVD 38 (17) 15 (22) .366
Carotid artery stenosis 34 (15) 11 (16) .847
Inotropic support 3 (1) 1 (1) 1.000
Preoperative IABP 8 (4) 2 (3) 1.000
Valve disease 34 (15) 7 (10) .425
Previous cardiac surgery 0 (0) 1 (1) .229
Acute MI 34 (15) 11 (16) .847
UA 126 (56) 35 (52) .675
2-Vessel disease 67 (30) 10 (15) .018
3-Vessel disease 149 (66) 55 (82) .015
Left main disease 60 (27) 11 (16) .105
Proximal LAD 87 (39) 23 (34) .568
LVEF 55 (10–80) 50 (20–70) .590
Emergent/urgent status 140 (62) 41 (61) 1.000
NYHA class 2 (1–4) 1 (1–4) .154
Baseline creatinine
1.5 mg/dL
14 (6) 7 (10) .272
euroSCORE 4 (0–14) 4 (0–12) .948
Intraoperative data
Planned 49/67 (73)
Off pump 35 (15) 15 (22) .198
Grafts (n) 2 (1–5) 2 (1–5) .001
OR time (min) 374 (138–664) 411 (230–744) .001
CPB time (min) 92 (28–284) 76 (33–175) .001
Aortic crossclamp time (min) 64 (12–152) 51 (18–111) .001
Perioperative outcomes
Operative mortality 5 (2) 1 (1) 1.000
Length of stay (d) 6 (1–32) 5 (3–97) .766
Postoperative complications
PCVA 3 (1) 1 (1) 1.000
ARF/RFHD 8 (4) 2 (3) 1.000
Bleeding/PRBC 3 38 (17) 12 (18) .854
Reoperation for bleeding 7 (3) 3 (4) .701
Tracheostomy 2 (1) 2 (3) .225
New atrial fibrillation 49 (22) 11 (16) .393
PLCOS 10 (4) 0 (0) .124
Composite outcome* 16 (7) 3 (4) .579
Data are presented as the median (range) or number (percentage). SYNTAX, Synergy
Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery;
CABG, coronary artery bypass grafting; HCR, hybrid coronary revascularization; CHF,
congestive heart failure;COPD, chronic obstructive pulmonary disease;PVD, peripheral
vascular disease; IABP, intra-aortic balloon pump;LAD, left anterior descending (artery);
MI, myocardial infarction;UA, unstable angina; LVEF, left ventricular ejection fraction;
NYHA, New York Heart Association (functional classification); euroSCORE, European
System for Cardiac Operative Risk Evaluation;OR, operating room;CPB, cardiopulmo-
nary bypass; PCVA, postoperative cerebrovascular accident; ARF/RFHD, acute renal
failure/renal failure requiring hemodialysis; PLCOS, postoperative low cardiac output
syndrome. *Composite cardiac and cerebrovascular outcome: operative mortality, MI,
PCVA, PLCOS.
TABLE 2. Preoperative, intraoperative, and postoperative data for
SYNTAX 33 (n ¼ 88)
Variable
CABG
(n ¼ 75)
HCR
(n ¼ 13)
P
value
Preoperative data
Age (y) 62 (36–83) 74 (53–84) .015
Men 62 (83) 8 (62) .129
Diabetes 24 (32) 4 (31) 1.000
Hypertension 65 (87) 10 (77) .399
Dyslipidemia 59 (79) 9 (69) .481
Cardiogenic shock 1 (1) 0 (0) 1.000
CHF 11 (15) 1 (5) .450
COPD 23 (31) 2 (16) .334
History of stroke 11 (15) 2 (10) .729
PVD 11 (15) 4 (31) .224
Carotid artery stenosis 10 (13) 2 (15) 1.000
Inotropic support 2 (3) 0 (0) 1.000
Preoperative IABP 2 (3) 1 (5) .512
Valve disease 7 (9) 2 (16) .616
Previous cardiac surgery 3 (4) 0 (0) 1.000
Acute MI 9 (12) 2 (15) .663
UA 34 (45) 6 (46) 1.000
2-Vessel disease 14 (19) 3 (23) .710
3-Vessel disease 55 (73) 10 (77) 1.000
Left main disease 30 (40) 3 (23) .355
Proximal LAD 26 (35) 4 (31) 1.000
EF 50 (10–70) 50 (20–65) .415
Emergent/urgent status 38 (51) 7 (54) 1.000
NYHA class 2 (1–4) 2 (1–3) .849
Baseline creatinine 1.5 mg/dL 12 (16) 0 (0) .200
euroSCORE 4 (0–15) 6 (1–14) .045
Intraoperative data
Planned 11/13 (85)
Off pump 12 (16) 4 (31) .243
Grafts (n) 2 (1–5) 1 (1–2) .001
OR time (min) 378 (250–667) 405 (294–549) .404
CPB time (min) 91 (32–153) 64 (50–159) .090
Aortic crossclamp time (min) 61 (21–108) 38 (23–75) .041
Perioperative data
Operative mortality 0 (0) 3 (23)* .003
Length of stay (d) 6 (3–63) 6 (1–32) .364
Postoperative complications
PCVA 1 (1) 1 (8) .275
ARF/RFHD 4 (5) 0 (0) 1.000
Bleeding/PRBC 3 U 10 (13) 4 (31) .210
Reoperation for bleeding 0 (0) 0 (0)
Tracheostomy 1 (1) 2 (15) .056
New atrial fibrillation 17 (23) 4 (31) .501
PLCOS 3 (4) 2 (15) .156
Composite outcomey 4 (5) 4 (30) .015
Data are presented as the median (range) or number (percentage). SYNTAX, Synergy
Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; CABG,
coronary artery bypass grafting; HCR, hybrid coronary revascularization; CHF, conges-
tive heart failure; COPD, chronic obstructive pulmonary disease;MI, myocardial infarc-
tion; UA, unstable angina; PVD, peripheral vascular disease; IABP, intra-aortic balloon
pump; LAD, left anterior descending (artery); EF, ejection fraction; NYHA, New York
Heart Association (functional classification); euroSCORE, European System for Cardiac
Operative Risk Evaluation; OR, operating room; CPB, cardiopulmonary bypass; PCVA,
postoperative cerebrovascular accident; ARF/RFHD, acute renal failure/renal failure re-
quiring hemodialysis;PLCOS, postoperative low cardiac output syndrome. *HCR group,
2 planned and 1 unplanned. yComposite cardiac and cerebrovascular outcome: operative
mortality, MI, PCVA, PLCOS.
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TABLE 3. Preoperative, intraoperative, and postoperative data for
euroSCORE 5 (n ¼ 239)
Variable
CABG
(n ¼ 193)
HCR
(n ¼ 46)
P
value
Preoperative data
Age (y) 59 (32–80) 58 (39–75) .310
Men 157 (81) 38 (83) 1.000
Diabetes 65 (34) 21 (46) .171
Hypertension 152 (79) 39 (85) .419
Dyslipidemia 155 (80) 37 (80) 1.000
Cardiogenic shock 1 (1) 1 (2) .349
CHF 13 (7) 2 (4) .742
COPD 36 (19) 7 (16) .830
History of stroke 11 (6) 0 (0) .130
PVD 17 (9) 8 (17) .107
Carotid artery stenosis 13 (7) 5 (11) .357
Inotropic support 2 (1) 1 (2) .475
Preoperative IABP 2 (1) 1 (2) .475
Valve disease 14 (7) 2 (4) .744
Previous cardiac surgery 0 (0) 0 (0)
Acute MI 17 (9) 4 (9) 1.000
UA 97 (51) 21 (46) .623
2-Vessel disease 52 (27) 7 (15) .127
3-Vessel disease 1426 (65) 38 (83) .022
Left main disease 55 (29) 8 (17) .140
Proximal LAD 67 (35) 15 (33) .864
EF 55 (15–80) 55 (30–70) .942
Emergent/urgent status 112 (58) 24 (52) .510
NYHA class 2 (1–4) 1 (1–3) .600
Baseline creatinine
1.5 mg/dL
11 (6) 3 (7) .736
SYNTAX score 24.5 (7–46.5) 22.5 (12–41) .188
SYNTAX low score 80 (41) 22 (48) .044
SYNTAX medium score 65 (34) 20 (43) .044
SYNTAX high score 48 (25) 4 (9) .044
euroSCORE 3 (0–5) 2.5 (0–5) .606
Intraoperative data
Planned HCR 34/46 (74)
Off pump 27 (14) 7 (15) .816
Grafts (n) 2 (1–5) 2 (1–4) .001
OR time (min) 375 (138–667) 403 (230–744) .005
CPB time (min) 91 (28–178) 72 (33–143) .001
Aortic crossclamp
time (min)
64.5 (20–147) 50 (18–111) .001
Perioperative outcomes
Operative mortality 1 (1) 2 (4) .096
Length of stay (d) 5 (3–33) 5 (3–97) .694
(Continued)
TABLE 3. Continued
Variable
CABG
(n ¼ 193)
HCR
(n ¼ 46)
P
value
Postoperative complications
PCVA 1 (1) 0 (0) 1.000
ARF/RFHD 6 (3) 1 (2) 1.000
Bleeding/PRBC 3 U 24 (12) 8 (17) .347
Reoperation for bleeding 4 (2) 3 (7) .132
Tracheostomy 2 (1) 2 (4) .168
New atrial fibrillation 37 (19) 5 (11) .280
PLCOS 8 (4) 0 (0) .359
Composite outcome* 10 (5) 3 (7) .719
Data are presented as the median (range) or number (percentage). euroSCORE, Eu-
ropean System for Cardiac Operative Risk Evaluation; CABG, coronary artery bypass
grafting; HCR, hybrid coronary revascularization; CHF, congestive heart failure;
COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease;
IABP, intra-aortic balloon pump; MI, myocardial infarction; UA, unstable angina;
LAD, left anterior descending (artery); EF, ejection fraction; SYNTAX, Synergy Be-
tween Percutaneous Coronary Intervention With Taxus and Cardiac Surgery;
NYHA, New York Heart Association (functional classification); OR, operating
room;CPB, cardiopulmonary bypass; PCVA, postoperative cerebrovascular accident;
ARF/RFHD, acute renal failure/renal failure requiring hemodialysis; PLCOS, postop-
erative low cardiac output syndrome. *Composite cardiac and cerebrovascular out-
come: operative mortality, MI, PCVA, PLCOS.
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data were similar between the 2 groups. The cardiopulmo-
nary bypass time and ischemic time were shorter in HCR
group than in the CABG group (Table 3). In the HCR group,
the mean number of stents placed per patient was 2.0  1.4,
and most patients (91%) received a DES. The median num-
ber of grafts per patient in the CABG and HCR group was 2
(range, 1–5) and 2 (range, 1–4), respectively (P ¼ .001).The Journal of Thoracic and CarPatients with euroSCORE greater than 5. A total of 142
patients (108 CABG and 34 HCR) had a euroSCORE
greater than 5 (mean, 8  2). The preoperative and postop-
erative data were similar between the 2 groups. The total op-
erating room time was longer in the HCR group than in the
CABG group (Table 4). Of these patients, 85% received
a DES and 15% a BMS, with a mean number of stents
per patient of 2.2  1.1. The median number of grafts per
patient in the CABG and HCR group was 2 (range, 1–5).Stratification by Both SYNTAX and euroSCORE
(2 3 2 Matrix)
Thematrix depicted in Figure 1 is divided by the high and
low SYNTAX score and low and high euroSCORE. The
columns represent division into high and low SYNTAX
scores. The rows represent division into the high and low
euroSCORE. Each of the 4 components of the matrix repre-
sents a different combination of high and low SYNTAX
scores and euroSCOREs and their effect on the 30-day com-
posite endpoint for CABG vs HCR.
Patients with SYNTAX of 32 or less and euroSCORE of
5 or Less. A total of 187 patients (145 CABG, 42 HCR)
had low coronary complexity and a low-risk profile. The
CABG group had a greater percentage of 3-vessel disease
and longer ischemic and cardiopulmonary bypass times
than the HCR group. The postoperative outcomes were sim-
ilar (Appendix Table 1). Of the 42 HCR patients, 93% re-
ceived a DES and 7% a BMS. Each patient received
a mean of 2.0  1.4 stents. The median number of grafts
per patient in the CABG and HCR groups was 2 (range,
1–5) and 2 (range, 1–4), respectively (P ¼ .001).diovascular Surgery c Volume 145, Number 4 1007
TABLE 4. Preoperative, intraoperative, and postoperative data for
euroSCORE>5 (n ¼ 142)
Variable
CABG
(n ¼ 108)
HCR
(n ¼ 34)
P
value
Preoperative data
Age (y) 71 (45–89) 73 (45–85) .056
Men 74 (69) 23 (68) 1.000
Diabetes 45 (42) 11 (32) .422
Hypertension 99 (92) 30 (88) .511
Dyslipidemia 74 (69) 21 (62) .532
Cardiogenic shock 3 (3) 0 (0) 1.000
CHF 22 (20) 4 (12) .317
COPD 35 (33) 12 (35) .836
History of stroke 17 (16) 5 (15) 1.000
PVD 32 (30) 11 (32) .831
Carotid artery stenosis 31 (29) 8 (24) .662
Inotropic support 3 (3) 0 (0) 1.000
Preoperative IABP 8 (7) 1 (3) .687
Valve disease 27 (25) 7 (21) .653
Previous cardiac surgery 2 (2) 1 (3) .563
Acute MI 26 (24) 9 (26) .821
UA 63 (58) 20 (59) 1.000
2-Vessel disease 29 (27) 6 (18) .363
3-Vessel disease 78 (72) 27 (79) .504
Left main disease 35 (32) 6 (18) .129
Proximal LAD 46 (43) 12 (35) .550
EF 50 (10–70) 50 (20–65) .695
Emergent/urgent status 66 (61) 24 (71) .415
NYHA class 2 (1–4) 2 (1–4) .056
Baseline creatinine
1.5 mg/dL
15 (14) 4 (12) 1.000
SYNTAX score 27 (11–56) 26.5 (13–44.5) .920
SYNTAX low score 35 (32) 13 (38) .725
SYNTAX medium score 46 (43) 12 (35) .725
SYNTAX high score 27 (25) 9 (27) .725
euroSCORE 7 (6–15) 8 (6–14) .472
Intraoperative data
Planned HCR 26/34 (76)
Off pump 20 (19) 12 (35) .058
Grafts (n) 2 (1–5) 2 (1–5) .001
OR time (min) 380 (234–558) 418 (264–593) .030
CPB time (min) 93 (32–284) 75 (36–175) .131
Aortic crossclamp
time (min)
61.5 (12–152) 54.5 (21–96) .090
Perioperative outcomes
Operative mortality 4 (4) 2 (6) .630
Length of stay (d) 6 (1–63) 6 (1–25) .481
(Continued)
TABLE 4. Continued
Variable
CABG
(n ¼ 108)
HCR
(n ¼ 34)
P
value
Postoperative complications
PCVA 3 (3) 2 (6) .593
ARF/RFHD 6 (6) 1 (3) 1.000
Bleeding/PRBC 3 U 24 (22) 8 (24) 1.000
Reoperation for bleeding 3 (3) 0 (0) 1.000
Tracheostomy 1 (1) 2 (6) .142
New atrial fibrillation 29 (27) 10 (29) .827
PLCOS 5 (5) 2 (6) .673
Composite outcome* 10 (9) 4 (12) .743
Data are presented as the median (range) or number (percentage). euroSCORE,
European System for Cardiac Operative Risk Evaluation; CABG, coronary artery
bypass grafting; HCR, hybrid coronary revascularization; CHF, congestive heart
failure; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular
disease; IABP, intra-aortic balloon pump; LAD, left anterior descending (artery);
EF, ejection fraction; MI, myocardial infarction; UA, unstable angina; SYNTAX,
Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Sur-
gery; NYHA, New York Heart Association (functional classification); OR, operating
room; CPB, cardiopulmonary bypass; PCVA, postoperative cerebrovascular accident;
ARF/RFHD, acute renal failure/renal failure requiring hemodialysis; PLCOS, postop-
erative low cardiac output syndrome. *Composite cardiac and cerebrovascular
outcome: operative mortality, MI, PCVA, PLCOS.
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greater than 5. The group with a SYNTAX score of 32
or less and euroSCORE greater than 5 included 81 CABG
patients and 25 HCR patients. The outcomes were similar,
except that the HCR group had a longer operating room
time (Appendix Table 2). The mean number of stents placed
per patient in the HCR was 2.0  1.2, with most (88%) re-
ceiving a DES. The median number of grafts per patient in1008 The Journal of Thoracic and Cardiovascular Surthe CABG and HCR groups was 2 (range, 1–4) and 2 (range,
1–5), respectively (P ¼ .001).
Patients with SYNTAX of 33 or greater and euro-
SCORE of 5 or less. The patients with a SYNTAX of 33
or more and euroSCORE of 5 or less included 52 patients
(48 CABG, 4 HCR). The preoperative, intraoperative, and
postoperative data were similar (Appendix Table 3). Of
the 4 HCR patients, 3 (75%) received a DES and 1
(25%) a BMS, for a mean of 2.5 1.0 stents placed per pa-
tient. The median number of grafts in the CABG and HCR
groups was 2 (range, 1–4) and 1 (range, 1–2) respectively
(P ¼ .005).
Patients with SYNTAX of 33 or greater and euro-
SCORE greater than 5. In the final group of 36 patients
(27 CABG and 9 HCR), the HCR patients were older (me-
dian age, 77 vs 65 years; P¼ .001). The compositeMACCE
was 33% in the HCR group and 0% in the CABG group
(P ¼ .012). Bleeding complications and postoperative low
cardiac output syndrome were also more frequent in the
HCR group (Appendix Table 4). The mean number of stents
per patient was 2.4 0.9, with most patients receiving DES
(78%) and fewer (22%) BMS. The median number of
grafts per patient in the CABG and HCR groups was 2
(range, 1–5) and 1 (range, 1–2), respectively (P ¼ .027).
DISCUSSION
The principal finding of our study was that HCR is safe
and feasible for many patients with multivessel CAD. How-
ever, patients with SYNTAX of 33 or greater and euro-
SCORE greater than 5 experienced better outcomes with
standard CABG than with HCR. The present study focused
on the safety of HCR compared with standard CABG. Wegery c April 2013
FIGURE 1. The 30-day composite cardiac and cerebrovascular outcomes
in the coronary artery bypass grafting (CABG) group and hybrid coronary
revascularization (HCR) stratified by Synergy Between Percutaneous Cor-
onary Intervention With Taxus and Cardiac Surgery (SYNTAX) and Euro-
pean System for Cardiac Operative Risk Evaluation (euroSCORE).
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SCORE to identify patients suitable for HCR. The 30-day
rate of MACCE for HCR vs CABG was similar in patients
with a low to intermediate SYNTAX score (32). Among
patients in the HCR group with a high SYNTAX score,
the rate of MACCE significantly increased, but the out-
comes in the CABG group were not influenced by the SYN-
TAX score. Although the euroSCORE alone did not discern
MACCE, the HCR group had significantly greater MACCE
compared with the CABG group in patients with a combina-
tion of a SYNTAX score of 33 or greater and euroSCORE
greater than 5. Similar results were reported after the strat-
ification of patients with 3-vessel disease in the original
SYNTAX trial1 and Arterial Revascularization Therapies
Study Part registry.9 These results reflect the fact that the
complexity of the coronary lesion directly affects the out-
comes of PCI, and the success of CABG is primarily related
to the quality of the distal targets and patients’ overall
health, and not to the coronary lesions themselves. Our find-
ings suggest that HCR should be carefully scrutinized in pa-
tients with high (33) SYNTAX scores, in particular in
those with a concomitant high (>5) euroSCORE.
Few series have compared the results of HCR vs
CABG.6,10 In our previous report of HCR, we did not find
significant differences in the 30-day outcomes.6 Similarly,
in a series of 104 HCR patients with multivessel disease
who were propensity matched to 104 off-pump CABG pa-
tients, the 30-day outcomes were similar and the MACCE
at 18 months of follow-up was better in the HCR than inThe Journal of Thoracic and Carthe off-pump CABG group because of the high rate of read-
mission to the hospital and neurologic events in the CABG
group.10 This is in concordance with the observation from
the SYNTAX trial,1 underscoring the lower invasiveness
of PCI and lower stroke rate compared with standard
CABG.
The euroSCORE was developed from a multinational
European adult cardiac surgery database to provide a simple
additive risk model for the European cardiac surgery pa-
tients. In North America, the Society of Thoracic Surgeons
(STS) established a national adult cardiac surgery database
in 1989. The STS has developed an algorithm for the preop-
erative calculation of risk for CABG surgery using data col-
lected in the STS National Adult Cardiac Surgery Database.
Despite substantial demographic differences between the
North American patients and European patients, the euro-
SCORE, when tested using the STS national adult cardiac
surgery database, performs well and can be used as a risk
stratification tool.11 We chose to use the euroSCORE to dis-
cern the clinical risk profile of patients instead of the STS
risk algorithm because the euroSCORE has been shown to
have better discriminative power to predict 30-day mortal-
ity compared with the STS clinical algorithm used in
coronary artery bypass operations only.12 The better dis-
crimination power is related to the significant differences
between scores with regard to the initial patient population
on which each score design was based.
The SYNTAX score, calculated using lesion assessment
based on coronary angiography, provides a useful tool to ob-
jectively decide which patient is suitable for PCI vs CABG.
The SYNTAX score has not yet been validated for patients
with previous intervention (PCI or CABG) or in the setting
of acute myocardial infarction. In a post hoc analysis of
1397 patients enrolled in the Limus Eluted from A Durable
vs ERodable Stent coating (LEADERS) trial, the SYNTAX
score was applied to an all-comers population including
patients with acute coronary syndromes and with previous
PCI and had showed predictive discriminatory power for
risk assessment.13 In our study, the SYNTAX score provided
a useful tool for clinical decision making related to appropri-
ateness of hybrid revascularization vs standard CABG.
Study Limitations
The present study was an uncontrolled retrospective se-
ries, and patient treatment was decided by surgeon and
cardiologist preference. The number of HCR patients in
the combined SYNTAX and euroSCORE group was small,
and this could affect the incidence of events noted in this
group. A larger study is needed to better define the clinical
outcomes using the SYNTAX and euroSCORE between
CABG and HCR. We included patients with acute myocar-
dial infarction and previous PCI, which might have af-
fected the SYNTAX score. Similarly, the euroSCORE
has been shown to have lower predictive performancediovascular Surgery c Volume 145, Number 4 1009
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fore, in the high SYNTAX and high euroSCORE group,
the predictive value of the euroSCORE could be affected
negatively.
The present study tested the 30-day mortality and other
MACCE. We are currently in the process of studying the
1- and 3-year MACCE in both groups.CONCLUSIONS
The present study is the first to apply SYNTAX score and
euroSCORE to compare the safety outcomes in patients
who underwent HCR vs CABG. Both procedures offer
equal safety outcomes for most patients. However, in pa-
tients with complex coronary disease (as assessed by the
SYNTAX score) and a high clinical risk profile (as assessed
by the euroSCORE), CABG might offer superior 30-day
outcomes. A larger and prospective study with long-term
follow-up is necessary to validate these initial findings.References
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Definitions
Operative mortality: in-hospital death or death for any
reason occurring within or after 30 days postoperatively.
Hospital length of stay: hospital length of stay from the
date of surgery to the date of discharge.
Hypertension: if there was a documented history of hy-
pertension treated by antihypertensive medication before
surgery.
Myocardial infarction (MI): acute if present 7 days or less
from the last documented MI or evolving, if, at surgery,
Q waves or ST changes were present, along with a creatine
kinase-MB greater than 5% of the total creatine kinase.
Urgent surgery: procedure required during the same hos-
pitalization to minimize the risk of additional clinical
deterioration.
Emergent surgery: if ischemic dysfunction (ongoing is-
chemia despite maximal medical treatment or intra-aortic
balloon pump, acute/evolving MI, pulmonary edema re-
quiring intubation), or shock.
Low cardiac output syndrome: a cardiac index of 2.0
L/min/m2 or less, requiring triple inotropic support to main-
tain a systolic pressure greater than 90 mmHg for at least 30
minutes and/or placement of an intra-aortic balloon pump
and/or ventricular assist device.
Perioperative MI: appearance of new Q waves and/or
a creatine kinase-MB fraction of 100 IU/L or greater.
Bleeding: necessity for reexploration of the thorax for
suspected bleeding during the postoperative period.
Stroke: evidence in the postoperative period of a new cen-
tral neurologic deficit persisting for longer than 72 hours; if
the neurologic deficit resolved within 72 hours, it was con-
sidered a transient ischemic attack.
Acute renal failure: an increase in creatinine to twice the
preoperative value.gery c April 2013
APPENDIXTABLE 1. Preoperative, intraoperative, andpostoperative
data for euroSCORE<5/SYNTAX<32 (n ¼ 187)
Variable
CABG
(145)
HCR
(n ¼ 42)
P
value
Preoperative data
Age (y) 59 (32–80) 57.5 (39–75) .350
Men 115 (79) 36 (86) .505
Diabetes 52 (36) 19 (45) .284
Hypertension 111 (77) 37 (88) .132
Dyslipidemia 113 (78) 33 (79) 1.000
Cardiogenic shock 1 (1) 1 (2) .400
CHF 10 (7) 2 (5) 1.000
COPD 24 (17) 7 (17) 1.000
History of stroke 8 (6) 0 (0) .202
PVD 14 (10) 7 (17) .264
Carotid artery stenosis 9 (6) 4 (10) .493
Inotropic support 2 (1) 1 (2) .536
Preoperative IABP 2 (1) 1 (2) .536
Valve disease 13 (9) 2 (5) .527
Previous cardiac surgery 0 (0) 0 (0)
Acute MI 15 (10) 4 (10) 1.000
UA 76 (53) 19 (45) .483
2-Vessel disease 40 (28) 6 (14) .103
3-Vessel disease 95 (66) 35 (83) .035
Left main disease 35 (24) 7 (17) .402
Proximal LAD 54 (37) 14 (33) .718
LVEF 55 (25–70) 55 (30–70) .914
Emergent/urgent status 84 (58) 22 (52) .597
NYHA class 2 (1–4) 1 (1–3) .471
Baseline creatinine 1.5 mg/dL 6 (4) 3 (7) .423
SYNTAX 21.5 (7–32) 21 (12–32) .612
euroSCORE 3 (0–5) 2.5 (0–5) .662
Intraoperative data
Planned HCR 32/42 (76)
Off pump 22 (15) 7 (17) .811
Grafts (n) 2 (1–5) 2 (1–4) .001
OR time (min) 371 (138–664) 403 (230–744) .004
CPB time (min) 90 (28–178) 76 (33–140) .001
Aortic crossclamp time (min) 64 (20–147) 51 (18–111) .001
Perioperative outcomes
Operative mortality 1 (1) 1 (2) .400
Length of stay (d) 5 (3–28) 5 (3–97) .993
Postoperative complications
PCVA 0 (0) 0 (0)
ARF/RFHD 4 (3) 1 (2) 1.000
Bleeding/PRBC 3 U 17 (12) 8 (19) .301
Reoperation for bleeding 4 (3) 3 (7) .198
Tracheostomy 1 (1) 1 (2) .400
New atrial fibrillation 25 (17) 4 (10) .332
PLCOS 5 (3) 0 (0) .589
Composite outcome* 6 (4) 2 (5) 1.000
Data are presented as the median (range) or number (percentage). euroSCORE,
European System for Cardiac Operative Risk Evaluation; SYNTAX, Synergy Between
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; CABG, coro-
nary artery bypass grafting; HCR, hybrid coronary revascularization; CHF, conges-
tive heart failure; COPD, chronic obstructive pulmonary disease; PVD, peripheral
vascular disease; IABP, intra-aortic balloon pump;MI,myocardial infarction;UA, un-
stable angina; LAD, left anterior descending (artery); LVEF, left ventricular ejection
fraction;NYHA,NewYork Heart Association (functional classification);HCR, hybrid
coronary revascularization; OR, operating room; CPB, cardiopulmonary bypass;
PCVA, postoperative cerebrovascular accident; ARF/RFHD, acute renal failure/renal
failure requiring hemodialysis; PRBC, packed red blood cells; PLCOS, postoperative
low cardiac output syndrome. *Composite cardiac and cerebrovascular outcome:
operative mortality, MI, PCVA, PLCOS.
APPENDIXTABLE 2. Preoperative, intraoperative, andpostoperative
data for euroSCORE>5/SYNTAX<32 (n ¼ 106)
Variable
CABG
(n ¼ 81)
HCR
(n ¼ 25)
P
value
Preoperative data
Age (y) 72 (46–89) 72 (45–85) .941
Men 54 (67) 17 (68) 1.000
Diabetes 34 (42) 9 (36) .648
Hypertension 75 (93) 22 (88) .437
Dyslipidemia 57 (70) 16 (64) .623
Cardiogenic shock 2 (2) 0 (0) 1.000
CHF 15 (19) 3 (12) .554
COPD 24 (30) 10 (40) .464
History of stroke 10 (12) 3 (12) 1.000
PVD 24 (30) 8 (32) .808
Carotid artery stenosis 25 (31) 7 (28) 1.000
Inotropic support 1 (1) 0 (0) 1.000
Preoperative IABP 6 (7) 1 (4) 1.000
Valve disease 21 (26) 5 (20) .607
Previous cardiac surgery 0 (0) 1 (4) .236
Acute MI 19 (23) 7 (28) .791
UA 50 (62) 16 (64) 1.000
2-Vessel disease 27 (33) 4 (16) .132
3-Vessel disease 54 (67) 20 (80) .319
Left main disease 25 (31) 4 (16) .201
Proximal LAD 33 (41) 9 (36) .816
LVEF 55 (10–65) 50 (20–60) .375
Emergent/urgent status 56 (69) 19 (76) .619
NYHA class 2 (1–4) 1 (1–4) .168
Baseline creatinine 1.5 mg/dL 8 (10) 4 (16) .471
SYNTAX 23 (11–32) 22 (13–31) .797
euroSCORE 7 (6–14) 8 (6–12) .641
Intraoperative data
Planned HCR 17/25 (68)
Off pump 13 (16) 8 (32) .092
Grafts (n) 2 (1–4) 2 (1–5) .001
OR time (min) 385 (234–558) 413 (264–593) .038
CPB time (min) 94 (38–284) 76 (36–175) .109
Aortic crossclamp time (min) 62 (12–152) 58 (21–96) .154
Perioperative outcomes
Operative mortality 4 (5) 0 (0) .571
Length of stay (d) 6 (1–32) 6 (3–19) .603
Postoperative complications
PCVA 3 (4) 1 (4) 1.000
ARF/RFHD 4 (5) 1 (4) 1.000
Bleeding/PRBC 3 U 21 (26) 4 (16) .422
Reoperation for bleeding 3 (4) 0 (0) 1.000
Tracheostomy 1 (1) 1 (4) .418
New atrial fibrillation 24 (30) 7 (28) 1.000
PLCOS 5 (6) 0 (0) .590
Composite outcome* 10 (12) 1 (4) .452
Data are presented as the median (range) or number (percentage). euroSCORE,
European System for Cardiac Operative Risk Evaluation; SYNTAX, Synergy Between
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; CABG, coro-
nary artery bypass grafting; HCR, hybrid coronary revascularization; CHF, conges-
tive heart failure; COPD, chronic obstructive pulmonary disease; PVD, peripheral
vascular disease; IABP, intra-aortic balloon pump; MI, myocardial infarction; UA,
unstable angina; LAD, left anterior descending (artery); LVEF, left ventricular
ejection fraction; NYHA, New York Heart Association (functional classification);
HCR, hybrid coronary revascularization;OR, operating room;CPB, cardiopulmonary
bypass; PCVA, postoperative cerebrovascular accident; ARF/RFHD, acute renal fail-
ure/renal failure requiring hemodialysis; PRBC, packed red blood cells; PLCOS,
postoperative low cardiac output syndrome. *Composite cardiac and cerebrovascular
outcome: operative mortality, MI, PCVA, PLCOS.
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APPENDIXTABLE 3. Preoperative, intraoperative, andpostoperative
data for euroSCORE<5/SYNTAX>33 (n ¼ 52)
Variable
CABG
(n ¼ 48)
HCR
(n ¼ 4)
P
value
Preoperative data
Age (y) 60 (36–80) 59.5 (53–64) .877
Men 42 (88) 2 (50) .107
Diabetes 13 (27) 2 (50) .569
Hypertension 41 (85) 2 (50) .134
Dyslipidemia 42 (88) 4 (100) 1.000
Cardiogenic shock 0 (0) 0 (0)
CHF 3 (6) 0 (0) 1.000
COPD 12 (25) 0 (0) .562
History of stroke 3 (6) 0 (0) 1.000
PVD 3 (6) 1 (25) .281
Carotid artery stenosis 4 (8) 1 (25) .341
Inotropic support 0 (0) 0 (0)
Preoperative IABP 0 (0) 0 (0)
Valve disease 1 (2) 0 (0) 1.000
Previous cardiac surgery 1 (2) 0 (0) 1.000
MI 2 (4) 0 (0) 1.000
UA 21 (44) 2 (50) 1.000
2-Vessel disease 12 (25) 1 (25) 1.000
3-Vessel disease 31 (65) 3 (75) 1.000
Left main disease 20 (42) 1 (25) .639
Proximal LAD 13 (27) 1 (25) 1.000
LVEF 53 (15–70) 47.5 (45–55) .507
Emergent/urgent status 28 (58) 2 (50) 1.000
NYHA class 2 (1–3) 1.5 (1–3) .755
Baseline creatinine 1.5 mg/dL 5 (10) 0 (0) 1.000
SYNTAX 36 (33–46.5) 36.8 (34–41) .809
euroSCORE 3 (0–5) 2.5 (1–4) .780
Intraoperative data
Planned HCR 2/4 (50)
Off pump 5 (10) 0 (0) 1.000
Grafts (n) 2 (1–4) 1 (1–2) .005
OR time (min) 379 (250–667) 394 (370–437) .607
CPB time (min) 91 (49–153) 67 (50–93) .079
Aortic crossclamp time (min) 65 (31–108) 40 (32–75) .090
Perioperative outcomes
Operative mortality 0 (0) 1 (25)* .077
Length of stay (d) 5 (3–33) 6.5 (5–32) .132
Postoperative complications
PCVA 1 (2) 0 (0) 1.000
ARF/RFHD 2 (4) 0 (0) 1.000
Bleeding/PRBC 3 U 7 (15) 0 (0) 1.000
Reoperation for bleeding 0 (0) 0 (0)
Tracheostomy 1 (2) 1 (25) .149
New atrial fibrillation 12 (25) 1 (25) 1.000
PLCOS 3 (6) 0 (0) 1.000
Composite outcomey 4 (8) 1 (25) .341
Data are presented as the median (range) or number (percentage). euroSCORE,
European System for Cardiac Operative Risk Evaluation; SYNTAX, Synergy Between
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; CABG, coro-
nary artery bypass grafting;HCR, hybrid coronary revascularization;CHF, congestive
heart failure;COPD, chronic obstructive pulmonary disease;PVD, peripheral vascular
disease; IABP, intra-aortic balloon pump;MI,myocardial infarction;UA, unstable an-
gina; LAD, left anterior descending (artery); LVEF, left ventricular ejection fraction;
NYHA,NewYorkHeart Association (functional classification);HCR, hybrid coronary
revascularization;OR, operating room;CPB, cardiopulmonary bypass;PCVA, postop-
erative cerebrovascular accident; ARF/RFHD, acute renal failure/renal failure requir-
ing hemodialysis; PRBC, packed red blood cells; PLCOS, postoperative low cardiac
output syndrome. *Respiratory failure. yComposite cardiac and cerebrovascular
outcome: operative mortality, MI, PCVA, PLCOS.
APPENDIXTABLE 4. Preoperative, intraoperative, andpostoperative
data for euroSCORE>5/SYNTAX>33 (n ¼ 36)
Variable
CABG
(n ¼ 27)
HCR
(n ¼ 9)
P
value
Preoperative data
Age (y) 65 (45–83) 77 (47–84) .001
Men 20 (74) 6 (67) .686
Diabetes 11 (41) 2 (22) .438
Hypertension 24 (89) 8 (89) 1.000
Dyslipidemia 17 (63) 5 (56) .712
Cardiogenic shock 1 (4) 0 (0) 1.000
CHF 7 (26) 1 (11) .648
COPD 11 (41) 2 (22) .438
History of stroke 7 (26) 2 (22) 1.000
PVD 8 (30) 3 (33) 1.000
Carotid artery stenosis 6 (22) 1 (11) .652
Inotropic support 2 (7) 0 (0) 1.000
Preoperative IABP 2 (7) 0 (0) 1.000
Valve disease 6 (22) 2 (22) 1.000
Previous cardiac surgery 2 (7) 0 (0) 1.000
MI 7 (26) 2 (22) 1.000
UA 13 (48) 4 (44) 1.000
2-Vessel disease 2 (7) 2 (22) .255
3-Vessel disease 24 (89) 7 (78) .581
Left main disease 10 (37) 2 (22) .685
Proximal LAD 13 (48) 3 (33) .700
LVEF 43 (10–70) 55 (20–65) .069
Emergent/urgent status 10 (37) 5 (56) .443
NYHA class 2 (1–4) 2 (1–3) .120
Baseline creatinine 1.5 mg/dL 7 (26) 0 (0) .156
SYNTAX 36.5 (33–56) 35.5 (33–44.5) .621
euroSCORE 7 (6–15) 9 (6–14) .562
Intraoperative data
Planned HCR 9/9 (100)
Off pump 7 (26) 4 (44) .409
Grafts (n) 2 (1–5) 1 (1–2) .027
OR time (min) 377 (275–519) 423 (294–549) .522
CPB time (min) 91 (32–141) 60 (58–159) .659
Aortic crossclamp time (min) 57 (21–97) 38 (23–74) .377
Perioperative outcomes
Operative mortality 0 (0) 2 (22) .057
Length of stay (d) 6 (4–63) 6 (1–25) .630
Postoperative complications
PCVA 0 (0) 1 (11) .250
ARF/RFHD 2 (7) 0 (0) 1.000
Bleeding/PRBC 3 U 3 (11) 4 (44) .050
Reoperation for bleeding 0 (0) 0 (0)
Tracheostomy 0 (0) 1 (11) .250
New atrial fibrillation 5 (19) 3 (33) .384
PLCOS 0 (0) 2 (22) .057
Composite outcome* 0 (0) 3 (33) .012
Data are presented as the median (range) or number (percentage). euroSCORE,
European System for Cardiac Operative Risk Evaluation; SYNTAX, Synergy Between
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; CABG,
coronary artery bypass grafting; HCR, hybrid coronary revascularization; CHF,
congestive heart failure; COPD, chronic obstructive pulmonary disease; PVD, pe-
ripheral vascular disease; IABP, intra-aortic balloon pump;MI,myocardial infarction;
UA, unstable angina; LAD, left anterior descending (artery); LVEF, left ventricular
ejection fraction; NYHA, New York Heart Association (functional classification);
HCR, hybrid coronary revascularization;OR, operating room;CPB, cardiopulmonary
bypass; PCVA, postoperative cerebrovascular accident; ARF/RFHD, acute renal fail-
ure/renal failure requiring hemodialysis; PRBC, packed red blood cells; PLCOS,
postoperative low cardiac output syndrome. *Composite cardiac and cerebrovascular
outcome: operative mortality, MI, PCVA, PLCOS.
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